Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion

被引:144
作者
Wang, Yue [1 ,2 ]
Xu, Rui Cheng [2 ]
Zhang, Xiao Lei [1 ]
Niu, Xiu Long [1 ]
Qu, Ye [3 ]
Li, Ling Zhi [2 ]
Meng, Xiang Yan [4 ]
机构
[1] Logist Coll Chinese Peoples Armed Police Forces, Dept Immunol, Tianjin 300162, Peoples R China
[2] Tianjin Key Lab Biomarkers Occupat & Environm Haz, Tianjin, Peoples R China
[3] Logist Coll Chinese Peoples Armed Police Forces, Dept Microbiol, Tianjin 300162, Peoples R China
[4] Logist Coll Chinese Peoples Armed Police Forces, Dept Physiol & Pathophysiol, Tianjin 300162, Peoples R China
基金
中国国家自然科学基金;
关键词
Interleukin-8(IL-8); Ovarian cancer (OVCA); Malignant behaviors; PI3K/Akt and Raf/MEK/ERK signaling; HUMAN BLADDER-CANCER; FACTOR-KAPPA-B; EXPRESSION REGULATES TUMORIGENICITY; PROSTATE-CANCER; CARCINOMA CELLS; FACTOR RECEPTOR; TUMOR-GROWTH; ENDOTHELIAL-CELLS; HUMAN-MELANOMA; UP-REGULATION;
D O I
10.1016/j.cyto.2012.04.013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
It has been shown that IL-8 is elevated in ovarian cyst fluid, ascites, serum, and tumor tissue from ovarian cancer (OVCA) patients, and increased IL-8 expression correlates with poor prognosis and survival. However, the exact role that IL-8 plays in this malignancy or whether IL-8 can regulate malignant behavior has not been established. Here we demonstrate that overexpression of IL-8 in non-IL-8-expressing A2780 cells (by transfecting with plasmid encoding for sense IL-8) increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion while depletion of endogenous IL-8 expression in IL-8-overexpressing SKOV-3 cells (by transfecting with plasmid encoding for antisense IL-8) decreases the above effects. Further investigation indicates that IL-8-stimulated cell proliferation correlates with alteration of cell cycle distribution by increasing levels of cell cycle-regulated Cyclin D1 and Cyclin B1 proteins as well as activation of PI3K/Akt and Raf/MEK/ERK, whereas IL-8-enhanced OVCA cell invasive correlates with increased MMP-2 and MMP-9 activity and expression. Our data suggest that IL-8 secreted by OVCA cells promotes malignant behavior of these cells via inducing intracellular molecular signaling. Therefore, modulation of IL-8 expression or its related signaling pathway may be a promising strategy for controlling the progression and metastasis of OVCA. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:145 / 155
页数:11
相关论文
共 57 条
[1]
Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].
Agarwal, R ;
Kaye, SB .
NATURE REVIEWS CANCER, 2003, 3 (07) :502-516
[2]
Alper Ö, 2000, INT J CANCER, V88, P566, DOI 10.1002/1097-0215(20001115)88:4<566::AID-IJC8>3.0.CO
[3]
2-D
[4]
Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer [J].
Araki, Shinako ;
Omori, Yohei ;
Lyn, Dominic ;
Singh, Rajendra K. ;
Meinbach, David M. ;
Sandman, Yekutiel ;
Lokeshwar, Vinata B. ;
Lokeshwar, Bal L. .
CANCER RESEARCH, 2007, 67 (14) :6854-6862
[5]
Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors:: correlation with Ki-67 and p53 immunoreactivity [J].
Bar, JK ;
Grelewski, P ;
Popiela, A ;
Noga, L ;
Rabczyñski, J .
GYNECOLOGIC ONCOLOGY, 2004, 95 (01) :23-31
[6]
Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro [J].
Brew, R ;
Erikson, JS ;
West, DC ;
Kinsella, AR ;
Slavin, J ;
Christmas, SE .
CYTOKINE, 2000, 12 (01) :78-85
[7]
Cheng GZ, 2008, CURR CANCER DRUG TAR, V8, P2
[8]
Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology [J].
Fasciani, A ;
D'Ambrogio, G ;
Bocci, G ;
Luisi, S ;
Artini, PG ;
Genazzani, AR .
FERTILITY AND STERILITY, 2001, 75 (06) :1218-1221
[9]
Giuntoli RL, 2009, ANTICANCER RES, V29, P2875
[10]
The selective CXCR2 antagonist SB272844 blocks interleukin-8 and growth-related oncogene-α-mediated inhibition of spontaneous neutrophil apoptosis [J].
Glynn, PC ;
Henney, E ;
Hall, IP .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2002, 15 (02) :103-110